VIVS — VivoSim Labs, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1497253 ·
Last close
$0.12
Market Cap
$2.44M
52W High
$3.40
52W Low
$0.12
ADV30
1,118,087
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 18,000 | — | -2,759,000 | -1,338,000 | 3,847,000 | 1,670,000 | 6,193,000 |
| Mar 2026 | 40,000 | 40,000 | -3,187,000 | -5,764,000 | 7,386,000 | 5,024,000 | 8,485,000 |
| Dec 2025 | 26,000 | 26,000 | -2,750,000 | -2,691,000 | 6,960,000 | 4,288,000 | 2,519,000 |
| Sep 2025 | 28,000 | 28,000 | -2,635,000 | -2,545,000 | 9,686,000 | 6,677,000 | 2,621,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,100,000
Investing CF
$71,000
Financing CF
$2,644,000
CapEx
$-23,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.40
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-357,338,000
Inventory
$0
Receivables
$1,045,000
ST Investments
—
EBIT TTM
$-12,321,000
Pretax Income TTM
$-12,333,000
Interest Exp TTM
$12,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$112,000
EBITDA
$-11,137,000
Free Cash Flow
$-7,575,375
Enterprise Value
$693,899
Total Cash
$1,670,000
Total Debt
$316,000
Shares Out
20,281,495
Trailing EPS
$-4.47
Book Value
$-0.38
ROE
-343.1%
ROA
-89.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 131,000 | -11,487,000 | -13,843,000 | 7,390,000 | 8,485,000 | -1,099,000 | -10,827,000 |
| Mar 2025 | 144,000 | -12,616,000 | -2,488,000 | 14,700,000 | 4,158,000 | 10,492,000 | -9,461,000 |
| Mar 2024 | 109,000 | -15,086,000 | -14,671,000 | 6,350,000 | 2,748,000 | 3,601,000 | -14,653,000 |
| Mar 2023 | 370,000 | -17,731,000 | -17,259,000 | 20,313,000 | 4,984,000 | 15,329,000 | -12,408,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$112,000
NetIncome TTM
$-12,338,000
OpCashFlow TTM
—
Assets (Latest)
$3,847,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABPO | Abpro Holdings, Inc. | $2.65M | $0.45 | — |
| CLDI | Calidi Biotherapeutics, Inc. | $2.06M | $0.56 | — |
| BCAB | BioAtla, Inc. | $3.00M | $1.80 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $3.02M | $0.10 | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $3.62M | $0.48 | — |
News headlines (Yahoo Finance, 1h cache)
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting
2026-11-16 13:05 · Yahoo
VivoSim: Fiscal Q2 Earnings Snapshot
2026-11-12 23:09 · Yahoo
VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
2026-11-10 13:05 · Yahoo
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
2026-11-03 13:05 · Yahoo
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
2026-10-21 12:05 · Yahoo
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
2026-10-07 12:05 · Yahoo
VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)
2026-07-21 14:28 · Yahoo
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
2026-07-21 12:05 · Yahoo
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
2026-07-16 12:30 · Yahoo
VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth
2026-07-15 14:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.